8 Tipping Points: Pharm Exec s 2019 Industry Forecast

Welcome once again to Pharm Exec s annual look at what s ahead for the biopharma industry, where we hope the eight trends singled out for this year capture the pulse of change and opportunity impacting leaders and decision-makers in the life sciences the most. From technology and digital hea Powered by WPeMatico Continue reading 8 Tipping Points: Pharm Exec s 2019 Industry Forecast

Future Pharma: Data Science as a Strategic Partner

Leaders at Novartis share how the big pharma is laying the foundations for a potential new operating model as a “medicines and data science company” At the beginning of 2018, Novartis CEO Vas Narasimhan spoke of reimagining Novartis as a medicines and data science com Powered by WPeMatico Continue reading Future Pharma: Data Science as a Strategic Partner

Securing a Winning Strategy for Real-World Evidence

While the increasing importance of real-world evidence (RWE) is widely acknowledged, the dramatic shift required by biopharma companies to embed and secure an RWE capability effectively across the organization is still a work in progress In Deloitte s Second Annual Real-World Powered by WPeMatico Continue reading Securing a Winning Strategy for Real-World Evidence

Pharma’s Image Fix: Lessons from the Field

The importance of an “adaptive” command style in pharma today Lieutenant General (Ret) Rick Lynch, US Army and Bob Jansen, CEO of Zensights, Pharm Exec Editorial Advisory Board member, and former president and general manager of Source Healthcare Analytics, a Symphony Powered by WPeMatico Continue reading Pharma’s Image Fix: Lessons from the Field

Accentuate the Positive: Tackling Pharma s Reputation Problem

Whether the pharma industry is navigating calm or choppy waters, it should be smarter and more assertive in telling its story to stakeholders Merck s Head Defends Drug Prices, ran The New York Times headline. The Times was reporting on the Merck & Co. president s Powered by WPeMatico Continue reading Accentuate the Positive: Tackling Pharma s Reputation Problem

The Innovation Distinction: Biopharma’s Reputational Pass

Fair or not, biotech has managed to elude perception crosshairs While traditional pharmaceutical companies are taking a reputational hit, biotech organizations, for the most part, are getting a public-perception pass for now. Whether or not it s fair, or accurate, in ge Powered by WPeMatico Continue reading The Innovation Distinction: Biopharma’s Reputational Pass

Health Policy Problem Solver: Fumie Griego

Turning Ideological Challenges into Practical Solutions The Geneva, Switzerland-based International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) represents research-based pharmaceutical companies and associations across the globe. It has consultative status w Powered by WPeMatico Continue reading Health Policy Problem Solver: Fumie Griego